Huahuang Pharmaceutical (China) Co., Ltd. (referred to as "Huahuang Pharmaceutical" or "HUTCHMED") announced that its partner Takeda has been approved by the Japanese Ministry of Health, Labour and Welfare to produce and sell FRUZAQLA (Fuquintinib) for the treatment of metastatic colorectal cancer patients. This means that Fruquintinib has become the first Chinese original new drug approved in the three major global mainstream markets of Europe, America, and Japan in Shanghai.